Want to see TSE:AYR.A full AI Analyst Report?
Ayr Wellness (AYR.A) AI Stock Analysis
Top Page
Ayr Wellness
(CNQX:AYR.A)
Ayr Wellness faces significant financial and operational challenges, with declining profitability, increasing debt, and negative cash flows. Technical indicators suggest bearish momentum, and valuation metrics are poor with a negative P/E ratio. The recent initiation of CCAA proceedings further highlights the company's financial distress.
Ayr Wellness (AYR.A) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 432.06K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 2.95
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Canada
- Employees
- 2,440
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Ayr Wellness Business Overview & Revenue Model
Company Description
Ayr Wellness Inc. is a vertically integrated, multi-state cannabis company that handles the cultivation, manufacturing, and retail sales of its own branded cannabis products. Their diverse product line includes items such as concentrates, edibles, an...
How the Company Makes Money
Ayr Wellness generates revenue through multiple key streams, primarily from the sale of cannabis products in both retail and wholesale markets. The company operates a network of dispensaries that sell its branded products directly to consumers, which...
Ayr Wellness Earnings Call Summary
The call highlighted strategic moves to strengthen the business through operational streamlining and market expansion, particularly in Ohio. However, significant challenges persist, including price compression and various operational difficulties, leading to a decline in profitability and substantial impairment charges.
Q4-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Ayr Wellness fourth quarter and full-year 2024 earnings call, Interim CEO Steven Cohen and President George DeNardo discussed the company's strategic focus on sustainable growth and profitability amidst industry challenges. The call highlighted that full-year sales remained flat at $463.6 million compared to the previous year, with retail sales declining by 4% and wholesale sales increasing by 28%. Adjusted gross margin was reported at 51.6%, down from 55% the previous year, primarily due to price compression and a shift in revenue from retail to wholesale. Ayr emphasized its commitment to core markets, including Florida, Ohio, and Pennsylvania, and announced plans to divest non-core assets like those in Illinois. The $10 million CapEx guidance for 2025, excluding potential Virginia investments, reflects a careful approach to capital deployment. Ayr's leadership transition includes the upcoming departure of CFO Brad Asher, with a focus on building a resilient leadership team to drive future success.
Ayr Wellness Financial Statement Overview
Summary
Ayr Wellness is experiencing financial challenges, with declining profitability, increasing debt levels, and negative cash flows. The company needs to improve operational efficiency and manage its leverage to stabilize its financial position.
Income Statement
45NeutralBalance Sheet
50NeutralCash Flow
40Negative| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 452.90M | 463.63M | 463.63M | 465.62M | 357.61M | 155.11M |
| Gross Profit | 158.83M | 176.68M | 202.44M | 190.44M | 138.10M | 103.10M |
| EBITDA | -96.32M | -154.53M | 84.60M | -67.66M | 87.69M | 17.21M |
| Net Income | -310.37M | -359.31M | -272.43M | -245.47M | -16.95M | -176.33M |
Balance Sheet | ||||||
| Total Assets | 1.26B | 1.27B | 1.46B | 1.76B | 1.86B | 615.87M |
| Cash, Cash Equivalents and Short-Term Investments | 37.64M | 35.48M | 50.77M | 80.64M | 154.34M | 127.24M |
| Total Debt | 634.32M | 621.88M | 597.77M | 621.66M | 483.82M | 190.62M |
| Total Liabilities | 946.67M | 904.31M | 889.20M | 928.56M | 839.85M | 465.01M |
| Stockholders Equity | 324.33M | 379.53M | 581.78M | 833.32M | 1.02B | 150.86M |
Cash Flow | ||||||
| Free Cash Flow | -9.58M | -15.14M | -12.44M | -96.66M | -127.78M | 21.74M |
| Operating Cash Flow | 11.68M | 9.63M | 27.16M | -34.16M | -27.78M | 36.51M |
| Investing Cash Flow | -18.34M | -21.81M | -24.15M | -66.50M | -219.63M | -62.25M |
| Financing Cash Flow | -26.90M | -3.10M | -32.89M | 26.96M | 274.51M | 144.57M |
Ayr Wellness Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AYR.A, the sentiment is Neutral. The current price of 0.15 is above the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.16, and below the 200-day MA of 0.16, indicating a neutral trend. The MACD of 0.00 indicates Neutral momentum. The RSI at is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:AYR.A.
Ayr Wellness Peers Comparison
Overall Rating
TSE:GTII75Outperform
TSE:CURA59Neutral
TSE:VRNO51Neutral- TSE:AYR.A40.1Neutral
TSE:CL40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:GTII | 75Outperform | CAD 1.90B | 11.41 | 6.82% | ― | 3.81% | 344.13% |
| TSE:CURA | 59Neutral | CAD 3.12B | -60.28 | -4.47% | ― | 1.50% | 81.84% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:VRNO | 51Neutral | CAD 2.17B | -1.65 | -28.93% | ― | 0.61% | 37.92% |
| TSE:AYR.A | 40Neutral | CAD 18.10M | -0.03 | -74.75% | ― | ― | ― |
| TSE:CL | 40Underperform | CAD 365.32M | -1.89 | -28.27% | ― | -5.83% | -115.39% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:AYR.A | Ayr Wellness Inc. | 0.15 | 0.00 | 0.00% | |
| TSE:CURA | Curaleaf Holdings (Otc) | 11.77 | 0.04 | 0.34% | |
| TSE:GTII | Green Thumb Industries (OTC) | 8.70 | -0.95 | -9.84% | |
| TSE:CL | Cresco Labs OTC | 0.80 | -0.83 | -50.92% | |
| TSE:VRNO | Verano Holdings Corp. | 6.32 | 0.00 | 0.00% |
Ayr Wellness Corporate Events
AYR Wellness Initiates CCAA Proceedings Amid Restructuring Efforts
NegativeAYR Wellness Inc. has initiated proceedings under the Companies’ Creditors Arrangement Act in Canada as part of its restructuring efforts. This move is aligned with a previously disclosed Restructuring Support Agreement, which involves transiti...
AYR Wellness Completes Auction, Initiates Core Asset Sale
NeutralAYR Wellness has announced the successful completion of a public foreclosure auction, resulting in its senior noteholders acquiring core assets through a new acquisition vehicle. This marks a significant milestone in AYR’s restructuring process...
AYR Wellness Initiates Article 9 Proceedings in Debt Restructuring
NeutralAYR Wellness has announced the commencement of Article 9 proceedings as part of its debt restructuring process with senior noteholders. This phase involves a foreclosure sale of certain assets and equity interests in specified subsidiaries across sev...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Dec 07, 2025